These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 6390386)

  • 21. [Gastroduodenal ulcer and Campylobacter pylori. Behavior under treatment with de-nol or metronidazole].
    Velasco Elizalde C; Quintero Díaz M; Soto Escobar A; Buesa Muñoz F; González Cansino J; Haedo Quiñones W
    G E N; 1987; 41(3):99-103. PubMed ID: 3149943
    [No Abstract]   [Full Text] [Related]  

  • 22. Bismuth compounds in the treatment of peptic ulcer: a review.
    Nanivadekar SA
    J Assoc Physicians India; 1990 Sep; 38 Suppl 1():736-42. PubMed ID: 2092031
    [No Abstract]   [Full Text] [Related]  

  • 23. Treating peptic ulcer: an ongoing challenge.
    Cohen MH
    J Am Osteopath Assoc; 1995 Apr; 95(4):239-41. PubMed ID: 7744624
    [No Abstract]   [Full Text] [Related]  

  • 24. Peptic ulcer treatment today--is there a role for maintenance therapy?
    Breslin NP; O'Morain C
    Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):116-21. PubMed ID: 9646190
    [No Abstract]   [Full Text] [Related]  

  • 25. Colloidal bismuth subcitrate in peptic ulcer--a review.
    Tytgat GN
    Digestion; 1987; 37 Suppl 2():31-41. PubMed ID: 3305117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absorption of bismuth from two bismuth compounds before and after healing of peptic ulcers.
    Hundal O; Bergseth M; Gharehnia B; Andersen KJ; Berstad A
    Hepatogastroenterology; 1999; 46(29):2882-6. PubMed ID: 10576366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De-Nol: mucosal protection and peptic ulcer disease. Proceedings of the De-Nol Symposium. September 8th, 1986, 8th World Congress of Gastroenterology, São Paulo.
    Digestion; 1987; 37 Suppl 2():1-64. PubMed ID: 3622944
    [No Abstract]   [Full Text] [Related]  

  • 28. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori.
    Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M
    J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662
    [No Abstract]   [Full Text] [Related]  

  • 29. There is more to healing ulcers than suppressing acid.
    Colin-Jones DG
    Gut; 1986 May; 27(5):475-80. PubMed ID: 3084343
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of peptic ulcer and gastritis associated with Helicobacter pylori].
    López-Brea M; Alarcón T
    Enferm Infecc Microbiol Clin; 1995; 13(7):422-8. PubMed ID: 8519820
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological and clinical aspects of some drugs used in peptic ulcer treatment.
    Abrahamsson H; Dotevall G
    Scand J Gastroenterol Suppl; 1979; 55():117-20. PubMed ID: 395633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report.
    Gasbarrini G; Malfertheiner P; Deltenre M; Mégraud F; O'Morain C; Pajares-García J; Quina M; Bianchi Porro G; Gasbarrini A; Franceschi F; Armuzzi A; Cammarota G; Anti M; Pretolani S
    Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S244-7. PubMed ID: 10077746
    [No Abstract]   [Full Text] [Related]  

  • 33. [Is bismuth subcitrate an effective drug for the patient with peptic ulcer?].
    Brouwers JR; Tytgat GN
    Ned Tijdschr Geneeskd; 1982 May; 126(18):795-8. PubMed ID: 7088206
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Endoscopic evaluation of healing of chronic gastric and duodenal ulcers after their local treatment].
    Buianov VM; Fokin NS; Perminova GI
    Sov Med; 1985; (12):31-3. PubMed ID: 4095628
    [No Abstract]   [Full Text] [Related]  

  • 37. Controlled trial comparing colloidal bismuth subcitrate tablets, cimetidine and placebo in the treatment of gastric ulceration.
    Tytgat GN; van Bentem N; van Olffen G; Dekker W; Rutgeerts L; de Boer J
    Scand J Gastroenterol Suppl; 1982; 80():31-8. PubMed ID: 6761850
    [No Abstract]   [Full Text] [Related]  

  • 38. Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro.
    Slomiany BL; Nishikawa H; Bilski J; Slomiany A
    Am J Gastroenterol; 1990 Apr; 85(4):390-3. PubMed ID: 2109526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease.
    Dresow B; Fischer R; Gabbe EE; Wendel J; Heinrich HC
    Scand J Gastroenterol; 1992 Apr; 27(4):333-6. PubMed ID: 1589712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current viewpoints on conservative ulcer therapy].
    Börsch G
    Med Welt; 1983 Mar; 34(10):316-20. PubMed ID: 6843329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.